Novartis AG - ADR
NVS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$303.67B
Close$
Earnings Call Q4 2025
February 4, 2026 - AI Summary
Strong Financial Performance: Novartis achieved an 8% sales increase and a 14% rise in core operating income for 2025, surpassing their guidance. They reached a core margin of 40.1%, two years earlier than planned, signaling strong operational execution and productivity improvements.
Sales Forecasts: For 2026, Novartis expects low single-digit sales growth, impacted by the entry of generics for key products like Entresto, Promacta, and Tasigna. The first half of 2026 is expected to see sales declining low single digit, while growth is anticipated in the second half, with mid-single-digit growth driven by priority brands.
Pipeline and Growth Drivers: The company highlighted several growth drivers, including a 57% increase in Kisqali sales and a strong performance from Scemblix and Pluvicto. Upcoming pivotal readouts for key pipeline products like pelabresib and remibrutinib are expected to bolster growth potential beyond 2026.
Exclusive for Stockcircle Pro members
Sign up
$199.82
21.1% upside
Current Fair Value
21.1% upsideUndervalued by 21.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $303.67 Billion |
|---|---|
| Enterprise Value | $344.98 Billion |
| Annual dividend | $4.74 |
| Dividend yield | 2.77% |
| Earnings per Share | $7.25 |
| Beta | 0.42 |
| Outstanding Shares | 1,896,000,000 |
Return
| Return on Equity | 23.92% |
|---|---|
| Return on Assets | 8.14% |
| Return on Invested Capital | 16.08% |
Valuation & Multiples
| P/E Ratio | 31.19 |
|---|---|
| PEG | -44.94 |
| Price to Sales | 5.69 |
| Price to Book Ratio | 7.5 |
| Enterprise Value to Revenue | 6.22 |
| Enterprise Value to EBIT | 23.82 |
| Enterprise Value to Net Income | 34 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 1.18 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 27, 2026
EPS Estimate
$2.25
Consensus analyst estimateRevenue Estimate
$14.53 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 3, 2027
EPS Estimate
$2.23
Consensus analyst estimateRevenue Estimate
$14.69 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 29.80, the ratio is above 1, so institutions hold more puts than calls. That is a more cautious stance.
| Put/Call Ratio | 29.8039▲ 2788.90% |
|---|---|
| Total Calls | 255▼ 99.99% |
| Total Puts | 7,600▼ 99.83% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.46%▼ 6.69% |
|---|---|
| Total Invested | $1.24B▼ 94.17% |
| Investors Holding | 677▼ 998.00% |
About Novartis AG
75,267 employees
CEO: Vasant Narasimhan
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...